CJC-1295 Effect on CMP (Comprehensive Metabolic Panel): What Labs Actually Change

What Is CJC-1295 and Why Does It Touch the CMP?

CJC-1295 modified GRF is a synthetic analogue of growth-hormone-releasing hormone (GHRH). It binds the pituitary GHRH receptor and amplifies the natural GH pulse, raising both GH and downstream IGF-1. Because GH acts on liver, muscle, adipose, and kidney tissue simultaneously, nearly every organ system tracked by a standard CMP can register a signal after sustained use.

Growth hormone is a counter-regulatory hormone. It opposes insulin at the receptor level, shifts substrate oxidation toward fat, and promotes protein synthesis through IGF-1 signaling. Each of those actions has a measurable lab correlate. That is why a CMP, not just an IGF-1 level, belongs in the monitoring plan.

The DAC Modification and Half-Life

Standard GHRH 1-29 has a plasma half-life under 10 minutes. CJC-1295 carries a drug-affinity complex (DAC) that covalently binds circulating albumin, extending the half-life to roughly 6-8 days in humans [1]. That prolonged exposure means GH and IGF-1 elevations are sustained rather than brief, which matters for interpreting CMP trends over weeks rather than hours.

Compounded Status and Dosing Context

CJC-1295 reaches patients through 503A compounding pharmacies as an off-label research peptide. Typical subcutaneous doses range from 100 mcg to 300 mcg per injection, one to three times weekly [1]. Higher cumulative weekly doses produce larger IGF-1 increases, and the magnitude of IGF-1 rise correlates with the degree of downstream metabolic changes visible on a CMP.

CJC-1295 and Fasting Glucose on the CMP

Fasting glucose is the CMP analyte most reliably affected by CJC-1295. GH acutely reduces peripheral glucose uptake by antagonizing insulin signaling at IRS-1 and downstream PI3K steps [2]. In Teichman et al. (2006), a double-blind, placebo-controlled study of 65 healthy adults receiving CJC-1295, mean IGF-1 rose 28-to-114 percent above baseline depending on dose [1]. IGF-1 increments of that magnitude are associated with measurable shifts in fasting glucose in acromegaly literature [3].

Magnitude of Expected Glucose Change

Acromegaly cohorts provide the clearest dose-response reference. A 2014 meta-analysis published in the European Journal of Endocrinology found that individuals with active acromegaly had fasting glucose approximately 1.2-1.8 mmol/L above age-matched controls [3]. CJC-1295 does not produce acromegaly-level IGF-1 elevations at standard doses, so the glucose shift expected in a peptide-therapy patient is smaller. A fasting glucose increase of 5-15 mg/dL above personal baseline is a reasonable clinical estimate, though individual responses vary.

Who Is Most Susceptible

Patients with pre-diabetes (fasting glucose 100-125 mg/dL) or insulin resistance carry the highest risk of a clinically meaningful glucose rise. The American Diabetes Association defines pre-diabetes at fasting glucose 100-125 mg/dL and recommends repeat fasting glucose every 1-2 years in at-risk individuals [4]. Applying that logic to CJC-1295 monitoring, a pre-diabetic patient on this peptide should recheck fasting glucose at 6 weeks rather than waiting 6 months.

Monitoring Glucose on CJC-1295

Check fasting glucose on every CMP draw. If baseline fasting glucose is <100 mg/dL, recheck at 6-8 weeks and again at 3 months. If baseline is 100-125 mg/dL, recheck at 4 weeks and consider adding HbA1c. A confirmed fasting glucose above 126 mg/dL on two draws warrants stopping the peptide and pursuing formal diabetes evaluation per ADA 2024 Standards of Care [4].

CJC-1295 and Liver Function Tests (ALT, AST, ALP, Total Bilirubin)

Liver function tests within the CMP reflect hepatocyte stress, cholestasis, and synthetic capacity. CJC-1295 does not carry a known direct hepatotoxic mechanism, but IGF-1, which is produced almost entirely in the liver, is synthesized at higher rates under GH stimulation [5]. Greater hepatic IGF-1 production means increased metabolic demand on hepatocytes.

ALT and AST

Mild transient ALT or AST elevations (typically <2x the upper limit of normal) have been observed anecdotally in peptide-therapy patients and in growth-hormone-replacement studies in GH-deficient adults [6]. The 2011 AACE Growth Hormone Deficiency Clinical Practice Guidelines note that GH replacement at therapeutic doses rarely causes sustained transaminase elevation, and values typically normalize within 4-8 weeks of dose reduction [7].

ALP and Bilirubin

Alkaline phosphatase may rise modestly with GH-stimulated bone turnover rather than hepatobiliary injury. IGF-1 promotes osteoblast activity, which elevates bone-fraction ALP independent of liver pathology [8]. Total bilirubin is not expected to change meaningfully with CJC-1295 at standard doses.

When to Act on Liver Values

An ALT or AST above 3x the upper limit of normal on a CMP drawn during CJC-1295 use should prompt dose reduction or temporary hold. The same threshold is used in FDA drug-induced liver injury guidance [9]. If values normalize within 4 weeks of dose reduction, a cautious re-challenge at a lower dose is reasonable. Persistent elevation above 3x warrants stopping the peptide entirely and ruling out co-existing causes.

CJC-1295 and Kidney Function (BUN, Creatinine, eGFR)

Short-term CJC-1295 use at standard subcutaneous doses is unlikely to produce clinically significant kidney function changes in patients with normal baseline renal function. Growth hormone does affect renal hemodynamics: GH increases glomerular filtration rate acutely in GH-deficient patients who begin GH replacement [10]. This represents a return toward normal GFR rather than a pathological increase.

BUN and Creatinine Trends

Creatinine is tied to muscle mass. Because GH and IGF-1 promote muscle protein synthesis, some patients on prolonged GH secretagogue therapy develop modestly increased lean mass. That lean mass gain may raise serum creatinine by 0.1-0.2 mg/dL without any change in true GFR [11]. A rising creatinine in a patient actively gaining muscle should prompt a cystatin-C measurement rather than automatic dose reduction.

eGFR and Pre-Existing CKD

Patients with pre-existing chronic kidney disease (eGFR <60 mL/min/1.73m2) require closer monitoring because IGF-1 receptors are expressed in mesangial and tubular cells [10]. No large RCT has specifically studied CJC-1295 in CKD patients. In the absence of that data, HealthRX protocols restrict CJC-1295 initiation to patients with eGFR above 60 and recheck creatinine and eGFR at 6-8 weeks.

Protein and Electrolyte Effects

GH promotes sodium retention through aldosterone-independent mechanisms, particularly at higher doses [12]. Mild peripheral edema is a recognized side effect of GH replacement therapy in GH-deficient adults [7]. On a CMP, this may appear as serum sodium at the upper end of the normal range (143-145 mEq/L) rather than overt hypernatremia. Potassium is generally unaffected.

CJC-1295 and Phosphorus

Phosphorus is not always included in a standard CMP panel, but many labs report it within the comprehensive panel or as an add-on. IGF-1 stimulates renal tubular phosphate reabsorption [8]. Patients with substantially elevated IGF-1 levels may develop phosphorus values at the upper end of the reference range (3.5-4.5 mg/dL in adults). This is the same mechanism responsible for the hyperphosphatemia seen in acromegaly [3].

Clinically, phosphorus values above 4.5 mg/dL during CJC-1295 therapy should raise the question of whether IGF-1 has risen above target. Check IGF-1 alongside the CMP if phosphorus is trending up.

CJC-1295 and Total Protein / Albumin

IGF-1 is a potent anabolic signal for hepatic protein synthesis. Total protein and albumin within the CMP may rise modestly with sustained GH secretagogue use, though values rarely leave the normal reference range in otherwise healthy adults [6]. A rising albumin in a malnourished or hypoalbuminemic patient starting CJC-1295 could actually represent therapeutic benefit.

Baseline CMP Before Starting CJC-1295

A complete CMP should be drawn in the fasted state before the first dose. This establishes personal reference values for glucose, transaminases, creatinine, and electrolytes. Without a baseline, attributing later changes to the peptide rather than pre-existing conditions becomes guesswork.

The HealthRX pre-treatment CMP checklist includes:

• Fasting glucose and, if pre-diabetic, HbA1c
• ALT, AST, ALP, total bilirubin
• BUN, creatinine, calculated eGFR
• Sodium, potassium, bicarbonate, chloride
• Total protein, albumin
• Calcium (for parathyroid and bone-health context)
• IGF-1 (age- and sex-adjusted reference range)

CMP Monitoring Schedule During CJC-1295 Therapy

The monitoring frequency depends on baseline risk. The table below reflects the HealthRX clinical protocol, derived from GH-deficiency monitoring literature [7] and adapted for the shorter pulse-amplitude changes typical of GHRH analogues.

| Patient Risk Profile | First Recheck | Ongoing Frequency | |---|---|---| | Healthy, normal baseline CMP | 6-8 weeks | Every 3-6 months | | Pre-diabetes (glucose 100-125 mg/dL) | 4 weeks | Every 3 months | | eGFR 60-89 (mild CKD risk) | 6 weeks | Every 3 months | | ALT/AST >1.5x ULN at baseline | 4 weeks | Every 6-8 weeks | | Age >60 with metabolic syndrome | 4 weeks | Every 3 months |

Draw the CMP in the fasted state, ideally 12-16 hours after the last meal and at least 24 hours after the last CJC-1295 injection. Acute post-injection GH surges can transiently alter glucose; drawing too soon inflates the apparent glucose signal.

What to Do With Abnormal CMP Values

If any single analyte crosses a pre-specified action threshold, the clinical response should be graded:

• Fasting glucose 126-140 mg/dL: reduce dose by 50 percent, recheck in 3 weeks, add HbA1c
• Fasting glucose >140 mg/dL on two draws: stop peptide, refer for diabetes workup
• ALT or AST 2-3x ULN: hold dose for 2 weeks, recheck; restart at lower dose if values normalize
• ALT or AST >3x ULN: stop peptide, investigate for alternate causes [9]
• Creatinine rise >0.3 mg/dL above personal baseline: check cystatin-C and urine protein:creatinine ratio
• Sodium >146 mEq/L with edema: reduce dose, reassess hydration

The Role of IGF-1 Alongside the CMP

A CMP alone cannot tell you whether a glucose or phosphorus change is GH-driven without a concurrent IGF-1 level. Draw IGF-1 at every CMP recheck during the dose-titration phase. The AACE 2011 guidelines recommend maintaining IGF-1 within the age-normalized reference range during GH therapy; values consistently above +2 SD for age should prompt dose reduction regardless of symptoms [7]. The same logic applies to CJC-1295: a rising CMP abnormality in the context of a supratherapeutic IGF-1 (>350 ng/mL in a 40-year-old, for example) points clearly to GH over-exposure.

Key Clinical Trial Data

The foundational human pharmacokinetic study for CJC-1295 is Teichman et al. (2006), published in the Journal of Clinical Endocrinology and Metabolism [1]. Sixty-five healthy adults received a single subcutaneous dose of CJC-1295 at 30, 60, 90, or 120 mcg/kg or placebo. Mean IGF-1 increased 28 percent in the lowest-dose group and 114 percent in the highest-dose group. GH levels remained elevated for 6 days post-injection. The authors concluded that "CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 levels in healthy adults and was safe and relatively well tolerated" [1]. No serious adverse changes in liver function, renal function, or electrolytes were reported at the doses studied, though the single-dose design limits conclusions about chronic CMP effects.

Longer-term GH-replacement data from the Hypopituitary Control and Complications Study (HypoCCS), which followed more than 13,000 GH-deficient patients on daily GH for up to 15 years, found no clinically meaningful deterioration in kidney or liver function versus controls [6]. Because CJC-1295 produces GH elevations far smaller than daily exogenous GH injections, HypoCCS data provide a reasonable upper-bound safety reference for CMP analytes.

The AACE 2011 Consensus Statement on growth hormone deficiency states: "IGF-1 should be monitored at each dosing adjustment visit and at least annually thereafter; fasting glucose and lipid panel should be assessed at baseline and after each major dose adjustment" [7]. That recommendation, written for exogenous GH replacement, transfers directly to GHRH analogue therapy as a clinical analog.

For glucose physiology, the ADA's 2024 Standards of Medical Care in Diabetes defines impaired fasting glucose as 100-125 mg/dL and recommends repeat testing every 1-2 years with lifestyle counseling [4]. Clinicians prescribing CJC-1295 to patients in this glycemic range should document the diabetes risk discussion and establish tighter CMP monitoring intervals than they would for a patient with truly normal fasting glucose.

GH-induced sodium retention mechanisms are detailed in a 2018 review in Endocrine Reviews, which confirmed that GH stimulates renal tubular sodium reabsorption through a mechanism partially dependent on IGF-1 and partially independent [12]. The same review noted that peripheral edema occurs in 10-20 percent of GH-deficient adults starting replacement therapy and typically resolves with dose reduction [12].

A 2019 study in the Journal of Clinical Endocrinology and Metabolism examining renal effects of GH in GH-deficient adults found that GFR increased by a mean of 12 percent within 12 weeks of starting GH replacement, returning toward pre-treatment GH-deficient baseline (which is itself lower than healthy controls) [10]. This GFR increase is likely hemodynamic and reversible rather than structural.

Drug Interactions That Amplify CMP Changes

Certain co-administered agents can amplify the CMP changes associated with CJC-1295.

Insulin or insulin secretagogues blunt the glucose signal. A patient already on metformin may not show fasting glucose elevation even with rising IGF-1, which could mask over-exposure to GH. Monitoring IGF-1 directly is essential in this population [4].

Glucocorticoids potentiate glucose elevation and may also blunt the GH response to CJC-1295 by promoting somatostatin tone [13]. A patient on prednisone 5-10 mg/day may need higher CJC-1295 doses to achieve IGF-1 targets but will also carry higher fasting glucose risk.

Thyroid hormone status modulates GH sensitivity. Hypothyroidism reduces IGF-1 generation from a given GH stimulus; untreated hypothyroidism may make CMP glucose changes appear smaller than they would be with euthyroid status [14]. Check TSH at baseline alongside the CMP.

Practical Takeaways for Prescribers and Patients

CJC-1295 modified GRF is not a zero-lab-impact peptide. The degree of CMP change depends on dose, injection frequency, individual GH axis sensitivity, and co-existing metabolic conditions.

Fasting glucose is the single most important CMP analyte to track. It should be measured at baseline, at 4-8 weeks, and at every subsequent recheck. Patients with fasting glucose at or above 100 mg/dL at baseline need a 4-week first recheck, not the standard 6-8 week interval.

Transaminases matter, though severe hepatotoxicity is not expected at standard doses. A 4-week recheck after any dose increase is good practice regardless of baseline values.

Creatinine and eGFR are unlikely to change meaningfully in patients with normal kidneys, but a cystatin-C level at the first recheck adds sensitivity for detecting early renal hemodynamic changes in higher-risk patients.

Draw the CMP fasted, at least 24 hours after the last CJC-1295 injection, and always pair it with an IGF-1 level during dose titration. An out-of-range CMP analyte only makes clinical sense when interpreted alongside the IGF-1 result.